0001104659-19-021852.txt : 20190417
0001104659-19-021852.hdr.sgml : 20190417
20190417093614
ACCESSION NUMBER: 0001104659-19-021852
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190417
FILED AS OF DATE: 20190417
DATE AS OF CHANGE: 20190417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRIEDLI PETER
CENTRAL INDEX KEY: 0001008317
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32966
FILM NUMBER: 19752334
MAIL ADDRESS:
STREET 1: FREIGUT STRASSE 5
STREET 2: 8002 ZURICH
CITY: SWITZERLAND
STATE: V8
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OSIRIS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001360886
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 710881115
STATE OF INCORPORATION: MD
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7015 ALBERT EINSTEIN DRIVE
CITY: COLUMBIA
STATE: MD
ZIP: 21046
BUSINESS PHONE: 443-545-1819
MAIL ADDRESS:
STREET 1: 7015 ALBERT EINSTEIN DRIVE
CITY: COLUMBIA
STATE: MD
ZIP: 21046
4
1
a4.xml
4
X0306
4
2019-04-17
1
0001360886
OSIRIS THERAPEUTICS, INC.
OSIR
0001008317
FRIEDLI PETER
C/O OSIRIS THERAPEUTICS, INC.
7075 ALBERT EINSTEIN DRIVE
COLUMBIA
MD
21046
1
0
0
0
Common Stock
2019-04-17
4
D
0
10204404
19.00
D
0
D
Common Stock
2019-04-17
4
D
0
4103301
19.00
D
0
I
By New Venturetec AG
Common Stock
2019-04-17
4
D
0
500000
19.00
D
0
I
By Daughter
Common Stock
2019-04-17
4
D
0
2750
19.00
D
0
I
By Spouse
On March 12, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Smith & Nephew Consolidated, Inc., a Delaware corporation ("Parent"), Papyrus Acquisition Corp., a Maryland corporation and a direct subsidiary of Parent ("Purchaser") and Smith & Nephew plc, an English public limited company. Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $19.00 per share (the "Offer Price") in cash.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Reporting Person disclaims beneficial ownership of these securities.
/s/ Peter Friedli
2019-04-17